Patent SG-11201906392W-A (SG)
Title: Nucleoside-modified rna for inducing an immune response against zika virus
Inventor: WEISSMAN DREW
IPC: A61K39/12
Filed: 2018-01-11
Abstract: CM . I \" c e lls ( %) .6 0,4 0.2 0.0 IL-2 4 • • • • • * • 0.8 o.e 0.4 0.2 0,0 Control ZIKV mRNA N 00 O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WIPO I PCT ill~~~~~~~~ 0mi110VIIIOH olo m1°111°11111 No oimIE (10) International Publication Number WO 2018/132537 Al (51) International Patent Classification: A61K 39/12 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/013270 (22) International Filing Date: 11 January 2018 (11.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/444,931 11 January 2017 (11.01.2017) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors: WEISSMAN, Drew; 218 Lloyd Lane, Wyn- newood, PA 19096 (US). PARDI, Norbert; 873 N. 23rd Street, Philadelphia, PA 19130 (US). HOGAN, Michael; 2205 Fitzwater Street, Apt. 2, Philadelphia, PA 19146 (US). (74) Agent: SINGH, Pallab et al.; Riverside Law, LLP, Glen- hardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE RESPONSE AGAINST ZIKA VIRUS Contml • ZIKV prM-E mRNA-LNP IFNy , 18 • • e• Control ZIKV mRNA. Go ZIKV mRNA (57) : The present invention relates to compositions and methods for inducing adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside- modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. Figure 1A 0 15 0.4 13 0.2 0.1 0.0 • • • e• • C57BL/6 iNr`